Form 4: Cognition Therapeutics CFO Acquires 295,000 Shares of Common Stock

John Brendan Doyle, CFO of Cognition Therapeutics, acquired 295,000 shares of common stock on February 4, 2025, through restricted stock units.

Summary

• On February 4, 2025, John Brendan Doyle, the Chief Financial Officer of Cognition Therapeutics Inc. (CGTX), acquired 295,000 shares of common stock.
• The acquisition was made through the granting of restricted stock units (RSUs), with each RSU representing the right to receive one share of the Issuer's Common Stock upon settlement.
• The price per share for the acquisition was $0.00.
• Following the transaction, Doyle directly owns 416,125 shares of Cognition Therapeutics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reflecting a change in ownership. The acquisition of shares by an executive is generally viewed as a positive signal, but without additional context, it's difficult to gauge the overall impact.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of insider transactions. This filing indicates a change in the beneficial ownership of Cognition Therapeutics' stock by one of its executives.

Key Dates